Gyre Therapeutics, Inc. Investment Income, Interest
Gyre Therapeutics, Inc. (GYRE) reported Investment Income, Interest of $224.00 thousand for the 3-month period ending 2013-03-31, per its 10-Q filed 2013-05-08.
Discontinued › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2013-05-08
- Gyre Therapeutics, Inc. investment income, interest for the quarter ending 2013-03-31 was $224.00K, a 25.08% decline year-over-year.
- Gyre Therapeutics, Inc. investment income, interest for the quarter ending 2012-12-31 was $252.00K, a 32.44% decline year-over-year.
- Gyre Therapeutics, Inc. investment income, interest for the quarter ending 2012-09-30 was $239.00K, a 24.37% decline year-over-year.
- Gyre Therapeutics, Inc. investment income, interest for the quarter ending 2012-06-30 was $280.00K, a 18.37% decline year-over-year.
- Gyre Therapeutics, Inc. investment income, interest for fiscal 2012 was $1.07M, a 20.62% decline from fiscal 2011.
- Gyre Therapeutics, Inc. investment income, interest for fiscal 2011 was $1.35M, a 7.86% decline from fiscal 2010.
- Gyre Therapeutics, Inc. investment income, interest for fiscal 2010 was $1.46M, a 39.33% increase from fiscal 2009.
- Gyre Therapeutics, Inc. investment income, interest for fiscal 2009 was $1.05M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2013-03-31 | $224.00K 10-Q · filed 2013-05-08 | $476.00K derived: sum of 2 quarters · filed 2013-05-08 | $715.00K derived: sum of 3 quarters · filed 2013-05-08 | $995.00K derived: sum of 4 quarters · filed 2013-05-08 |
| 2012-12-31 | $252.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | $491.00K derived: sum of 2 quarters · filed 2013-03-15 | $771.00K derived: sum of 3 quarters · filed 2013-03-15 | $1.07M 10-K · filed 2013-03-15 |
| 2012-09-30 | $239.00K 10-Q · filed 2012-11-08 | $519.00K derived: sum of 2 quarters · filed 2012-11-08 | $818.00K 10-Q · filed 2012-11-08 | $1.19M derived: sum of 4 quarters · filed 2013-05-08 |
| 2012-06-30 | $280.00K 10-Q · filed 2012-08-09 | $579.00K 10-Q · filed 2012-08-09 | $952.00K derived: sum of 3 quarters · filed 2013-05-08 | $1.27M derived: sum of 4 quarters · filed 2013-05-08 |
| 2012-03-31 | $299.00K 10-Q · filed 2013-05-08 | $672.00K derived: sum of 2 quarters · filed 2013-05-08 | $988.00K derived: sum of 3 quarters · filed 2013-05-08 | $1.33M derived: sum of 4 quarters · filed 2013-05-08 |
| 2011-12-31 | $373.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | $689.00K derived: sum of 2 quarters · filed 2013-03-15 | $1.03M derived: sum of 3 quarters · filed 2013-03-15 | $1.35M 10-K · filed 2013-03-15 |
| 2011-09-30 | $316.00K 10-Q · filed 2012-11-08 | $659.00K derived: sum of 2 quarters · filed 2012-11-08 | $975.00K 10-Q · filed 2012-11-08 | $1.34M derived: sum of 4 quarters · filed 2013-03-15 |
| 2011-06-30 | $343.00K 10-Q · filed 2012-08-09 | $659.00K 10-Q · filed 2012-08-09 | $1.02M derived: sum of 3 quarters · filed 2013-03-15 | $1.38M derived: sum of 4 quarters · filed 2013-03-15 |
| 2011-03-31 | $316.00K 10-Q · filed 2012-05-09 | $679.00K derived: sum of 2 quarters · filed 2013-03-15 | $1.04M derived: sum of 3 quarters · filed 2013-03-15 | $1.41M derived: sum of 4 quarters · filed 2013-03-15 |
| 2010-12-31 | $363.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | $723.00K derived: sum of 2 quarters · filed 2013-03-15 | $1.09M derived: sum of 3 quarters · filed 2013-03-15 | $1.46M 10-K · filed 2013-03-15 |
| 2010-09-30 | $360.00K 10-Q · filed 2011-11-03 | $726.00K derived: sum of 2 quarters · filed 2011-11-03 | $1.10M 10-Q · filed 2011-11-03 | |
| 2010-06-30 | $366.00K 10-Q · filed 2011-08-09 | $740.00K 10-Q · filed 2011-08-09 | ||
| 2009-12-31 | $1.05M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |